[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The hypothesis of this exploratory clinical trial in patients with high-grade a primary brain
tumor who receive chemoradiation is that the PET imaging agents [18F]Fluciclovine and/or
[18F]FLT will be a better predictor of tumor response than standard MRI based brain tumor
response criteria. When used in conjunction, the two PET agents may be better able to predict
tumor aggressiveness and thus overall survival than the use of individual-tracer PET
biomarkers. This may eventually lead to improved assessment of response (including time to
progression and overall survival) and differentiation of tumor recurrence/progression from
treatment effect (pseudoprogression).